메뉴 건너뛰기




Volumn 122, Issue 14, 2013, Pages 2318-2330

How I treat CNS lymphomas

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GADOLINIUM; IFOSFAMIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE;

EID: 84887643357     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-453084     Document Type: Review
Times cited : (143)

References (124)
  • 1
    • 0023891187 scopus 로고
    • Primary central nervous system lymphoma
    • Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68(6):835-853.
    • (1988) J Neurosurg , vol.68 , Issue.6 , pp. 835-853
    • Hochberg, F.H.1    Miller, D.C.2
  • 2
    • 33644851651 scopus 로고    scopus 로고
    • Primary CNS lymphoma
    • Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24(8):1281-1288.
    • (2006) J Clin Oncol , vol.24 , Issue.8 , pp. 1281-1288
    • Batchelor, T.1    Loeffler, J.S.2
  • 3
    • 80055000196 scopus 로고    scopus 로고
    • Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
    • Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414-1418.
    • (2011) Br J Cancer , vol.105 , Issue.9 , pp. 1414-1418
    • Villano, J.L.1    Koshy, M.2    Shaikh, H.3    Dolecek, T.A.4    McCarthy, B.J.5
  • 4
    • 79952193119 scopus 로고    scopus 로고
    • Survival among patients with primary central nervous system lymphoma, 1973-2004
    • Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2011;101(3):487-493.
    • (2011) J Neurooncol , vol.101 , Issue.3 , pp. 487-493
    • Norden, A.D.1    Drappatz, J.2    Wen, P.Y.3    Claus, E.B.4
  • 5
    • 84884930066 scopus 로고    scopus 로고
    • Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)
    • July Epub ahead of print
    • Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. July 2013 [Epub ahead of print].
    • (2013) J Clin Oncol
    • Rubenstein, J.L.1    Hsi, E.D.2    Johnson, J.L.3
  • 6
    • 38549128780 scopus 로고    scopus 로고
    • High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system
    • Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147-148.
    • (2008) Haematologica , vol.93 , Issue.1 , pp. 147-148
    • Illerhaus, G.1    Müller, F.2    Feuerhake, F.3    Schäfer, A.O.4    Ostertag, C.5    Finke, J.6
  • 7
    • 84877078929 scopus 로고    scopus 로고
    • Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - An International Primary Central Nervous System Lymphoma Study Group project
    • Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project. Haematologica. 2013;98(5):808-813.
    • (2013) Haematologica , vol.98 , Issue.5 , pp. 808-813
    • Bromberg, J.E.1    Doorduijn, J.K.2    Illerhaus, G.3
  • 8
    • 84874534353 scopus 로고    scopus 로고
    • Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas
    • Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364-370.
    • (2013) Haematologica , vol.98 , Issue.3 , pp. 364-370
    • Korfel, A.1    Elter, T.2    Thiel, E.3
  • 9
    • 84857098166 scopus 로고    scopus 로고
    • Immunochemotherapy with intensive consolidation for primary CNS lymphoma: A pilot study and prognostic assessment by diffusion-weighted MRI
    • Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146-1155.
    • (2012) Clin Cancer Res , vol.18 , Issue.4 , pp. 1146-1155
    • Wieduwilt, M.J.1    Valles, F.2    Issa, S.3
  • 10
    • 0032849190 scopus 로고    scopus 로고
    • Epidemiology of primary CNS lymphoma
    • Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol. 1999;43(3):199-201.
    • (1999) J Neurooncol , vol.43 , Issue.3 , pp. 199-201
    • Schabet, M.1
  • 11
    • 0034306288 scopus 로고    scopus 로고
    • Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas
    • Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol. 2000;18(19):3325-3330.
    • (2000) J Clin Oncol , vol.18 , Issue.19 , pp. 3325-3330
    • Cingolani, A.1    Gastaldi, R.2    Fassone, L.3
  • 12
    • 0037180541 scopus 로고    scopus 로고
    • Primary CNS lymphoma: A whole-brain disease?
    • Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59(10):1557-1562.
    • (2002) Neurology , vol.59 , Issue.10 , pp. 1557-1562
    • Lai, R.1    Rosenblum, M.K.2    DeAngelis, L.M.3
  • 13
    • 20244383617 scopus 로고    scopus 로고
    • Primary CNS lymphoma of T-cell origin: A descriptive analysis from the international primary CNS lymphoma collaborative group
    • Shenkier TN, Blay JY, O'Neill BP, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233-2239.
    • (2005) J Clin Oncol , vol.23 , Issue.10 , pp. 2233-2239
    • Shenkier, T.N.1    Blay, J.Y.2    O'Neill, B.P.3
  • 14
    • 23244461463 scopus 로고    scopus 로고
    • Pathology and genetics of primary central nervous system and intraocular lymphoma
    • vii
    • Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am. 2005;19(4):705-717, vii. [vii]
    • (2005) Hematol Oncol Clin North Am , vol.19 , Issue.4
    • Rubenstein, J.L.1    Treseler, P.2    O'Brien, J.M.3
  • 15
    • 0344927559 scopus 로고    scopus 로고
    • Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment
    • Montesinos-Rongen M, Küppers R, Schlüter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155(6):2077-2086.
    • (1999) Am J Pathol , vol.155 , Issue.6 , pp. 2077-2086
    • Montesinos-Rongen, M.1    Küppers, R.2    Schlüter, D.3
  • 16
    • 0037341470 scopus 로고    scopus 로고
    • BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma
    • Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res. 2003;9(3):1063-1069.
    • (2003) Clin Cancer Res , vol.9 , Issue.3 , pp. 1063-1069
    • Braaten, K.M.1    Betensky, R.A.2    De Leval, L.3
  • 17
    • 30144434561 scopus 로고    scopus 로고
    • A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases
    • Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190-196.
    • (2006) Blood , vol.107 , Issue.1 , pp. 190-196
    • Camilleri-Broët, S.1    Crinière, E.2    Broët, P.3
  • 18
    • 0036022074 scopus 로고    scopus 로고
    • Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system
    • Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer. 2002;35(1):38-48.
    • (2002) Genes Chromosomes Cancer , vol.35 , Issue.1 , pp. 38-48
    • Jordanova, E.S.1    Riemersma, S.A.2    Philippo, K.3    Giphart-Gassler, M.4    Schuuring, E.5    Kluin, P.M.6
  • 19
    • 33646411477 scopus 로고    scopus 로고
    • Gene expression and angiotropism in primary CNS lymphoma
    • Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107(9):3716-3723.
    • (2006) Blood , vol.107 , Issue.9 , pp. 3716-3723
    • Rubenstein, J.L.1    Fridlyand, J.2    Shen, A.3
  • 20
    • 42449093305 scopus 로고    scopus 로고
    • Pathway analysis of primary central nervous system lymphoma
    • Tun HW, Personett D, Baskerville KA, et al. Pathway analysis of primary central nervous system lymphoma. Blood. 2008;111(6):3200-3210.
    • (2008) Blood , vol.111 , Issue.6 , pp. 3200-3210
    • Tun, H.W.1    Personett, D.2    Baskerville, K.A.3
  • 21
    • 53149139859 scopus 로고    scopus 로고
    • Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: The importance of apoptosis and immunomodulatory pathways
    • Booman M, Szuhai K, Rosenwald A, et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol. 2008;216(2):209-217.
    • (2008) J Pathol , vol.216 , Issue.2 , pp. 209-217
    • Booman, M.1    Szuhai, K.2    Rosenwald, A.3
  • 22
    • 79955961315 scopus 로고    scopus 로고
    • The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications
    • Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
    • (2011) Blood , vol.117 , Issue.19 , pp. 5019-5032
    • Campo, E.1    Swerdlow, S.H.2    Harris, N.L.3    Pileri, S.4    Stein, H.5    Jaffe, E.S.6
  • 23
    • 54249117352 scopus 로고    scopus 로고
    • Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course
    • Cady FM, O'Neill BP, Law ME, et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008;26(29):4814-4819.
    • (2008) J Clin Oncol , vol.26 , Issue.29 , pp. 4814-4819
    • Cady, F.M.1    O'Neill, B.P.2    Law, M.E.3
  • 24
    • 0035026442 scopus 로고    scopus 로고
    • Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry
    • Harada K, Nishizaki T, Kubota H, Harada K, Suzuki M, Sasaki K. Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet Cytogenet. 2001;125(2):147-150.
    • (2001) Cancer Genet Cytogenet , vol.125 , Issue.2 , pp. 147-150
    • Harada, K.1    Nishizaki, T.2    Kubota, H.3    Harada, K.4    Suzuki, M.5    Sasaki, K.6
  • 25
    • 0042354212 scopus 로고    scopus 로고
    • Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: Frequent loss of chromosome arm 6q
    • Boonstra R, Koning A, Mastik M, van den Berg A, Poppema S. Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch. 2003;443(2):164-169.
    • (2003) Virchows Arch , vol.443 , Issue.2 , pp. 164-169
    • Boonstra, R.1    Koning, A.2    Mastik, M.3    Van Den Berg, A.4    Poppema, S.5
  • 26
    • 70350114261 scopus 로고    scopus 로고
    • Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma
    • Schwindt H, Vater I, Kreuz M, et al. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia. 2009;23(10):1875-1884.
    • (2009) Leukemia , vol.23 , Issue.10 , pp. 1875-1884
    • Schwindt, H.1    Vater, I.2    Kreuz, M.3
  • 27
    • 84866895485 scopus 로고    scopus 로고
    • Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas
    • Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203-5211.
    • (2012) Clin Cancer Res , vol.18 , Issue.19 , pp. 5203-5211
    • Gonzalez-Aguilar, A.1    Idbaih, A.2    Boisselier, B.3
  • 28
    • 52049095574 scopus 로고    scopus 로고
    • Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma
    • Courts C, Montesinos-Rongen M, Brunn A, et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol. 2008;67(7):720-727.
    • (2008) J Neuropathol Exp Neurol , vol.67 , Issue.7 , pp. 720-727
    • Courts, C.1    Montesinos-Rongen, M.2    Brunn, A.3
  • 29
    • 0037442987 scopus 로고    scopus 로고
    • Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas
    • Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 2003;63(4):737-741.
    • (2003) Cancer Res , vol.63 , Issue.4 , pp. 737-741
    • Nakamura, M.1    Kishi, M.2    Sakaki, T.3
  • 30
    • 79960297332 scopus 로고    scopus 로고
    • Primary central nervous system lymphomas: A validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens
    • Braggio E, McPhail ER, Macon W, et al. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011;17(13):4245-4253.
    • (2011) Clin Cancer Res , vol.17 , Issue.13 , pp. 4245-4253
    • Braggio, E.1    McPhail, E.R.2    Macon, W.3
  • 31
    • 34247118763 scopus 로고    scopus 로고
    • Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression
    • Courts C, Montesinos-Rongen M, Martin-Subero JI, et al. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol. 2007;66(3):230-237.
    • (2007) J Neuropathol Exp Neurol , vol.66 , Issue.3 , pp. 230-237
    • Courts, C.1    Montesinos-Rongen, M.2    Martin-Subero, J.I.3
  • 32
    • 77956192155 scopus 로고    scopus 로고
    • Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma
    • Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol. 2010;120(4):529-535.
    • (2010) Acta Neuropathol , vol.120 , Issue.4 , pp. 529-535
    • Montesinos-Rongen, M.1    Schmitz, R.2    Brunn, A.3
  • 34
    • 84878372110 scopus 로고    scopus 로고
    • Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma
    • Montesinos-Rongen M, Schäfer E, Siebert R, Deckert M. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol. 2012;124(6):905-906.
    • (2012) Acta Neuropathol , vol.124 , Issue.6 , pp. 905-906
    • Montesinos-Rongen, M.1    Schäfer, E.2    Siebert, R.3    Deckert, M.4
  • 35
    • 70349656791 scopus 로고    scopus 로고
    • CXCL13 and CXCL12 in central nervous system lymphoma patients
    • Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19):5968-5973.
    • (2009) Clin Cancer Res , vol.15 , Issue.19 , pp. 5968-5973
    • Fischer, L.1    Korfel, A.2    Pfeiffer, S.3
  • 36
    • 0037305275 scopus 로고    scopus 로고
    • Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma
    • Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood. 2003;101(3):815-821.
    • (2003) Blood , vol.101 , Issue.3 , pp. 815-821
    • Smith, J.R.1    Braziel, R.M.2    Paoletti, S.3    Lipp, M.4    Uguccioni, M.5    Rosenbaum, J.T.6
  • 37
    • 34247141490 scopus 로고    scopus 로고
    • Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1
    • Smith JR, Falkenhagen KM, Coupland SE, Chipps TJ, Rosenbaum JT, Braziel RM. Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol. 2007;127(4):633-641.
    • (2007) Am J Clin Pathol , vol.127 , Issue.4 , pp. 633-641
    • Smith, J.R.1    Falkenhagen, K.M.2    Coupland, S.E.3    Chipps, T.J.4    Rosenbaum, J.T.5    Braziel, R.M.6
  • 38
    • 84881057567 scopus 로고    scopus 로고
    • CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma
    • Rubenstein JL, Wong VS, Kadoch C, et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013;121(23):4740- 4748.
    • (2013) Blood , vol.121 , Issue.23 , pp. 4740-4748
    • Rubenstein, J.L.1    Wong, V.S.2    Kadoch, C.3
  • 39
    • 80052870189 scopus 로고    scopus 로고
    • Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas
    • Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro-oncol. 2011;13(10):1090-1098.
    • (2011) Neuro-oncol , vol.13 , Issue.10 , pp. 1090-1098
    • Fischer, L.1    Hummel, M.2    Korfel, A.3    Lenze, D.4    Joehrens, K.5    Thiel, E.6
  • 40
    • 37849044940 scopus 로고    scopus 로고
    • Protein biomarker identification in the CSF of patients with CNS lymphoma
    • Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008;26(1):96-105.
    • (2008) J Clin Oncol , vol.26 , Issue.1 , pp. 96-105
    • Roy, S.1    Josephson, S.A.2    Fridlyand, J.3
  • 41
    • 84859521316 scopus 로고    scopus 로고
    • Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)
    • Sasayama T, Nakamizo S, Nishihara M, et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro-oncol. 2012;14(3):368-380.
    • (2012) Neuro-oncol , vol.14 , Issue.3 , pp. 368-380
    • Sasayama, T.1    Nakamizo, S.2    Nishihara, M.3
  • 42
    • 79251573226 scopus 로고    scopus 로고
    • Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma
    • Sung CO, Kim SC, Karnan S, et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood. 2011;117(4):1291-1300.
    • (2011) Blood , vol.117 , Issue.4 , pp. 1291-1300
    • Sung, C.O.1    Kim, S.C.2    Karnan, S.3
  • 43
    • 79551686422 scopus 로고    scopus 로고
    • Oncogenically active MYD88 mutations in human lymphoma
    • Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
    • (2011) Nature , vol.470 , Issue.7332 , pp. 115-119
    • Ngo, V.N.1    Young, R.M.2    Schmitz, R.3
  • 44
    • 33846266260 scopus 로고    scopus 로고
    • The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia
    • Josephson SA, Papanastassiou AM, Berger MS, et al. The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg. 2007;106(1):72-75.
    • (2007) J Neurosurg , vol.106 , Issue.1 , pp. 72-75
    • Josephson, S.A.1    Papanastassiou, A.M.2    Berger, M.S.3
  • 45
    • 54549085770 scopus 로고    scopus 로고
    • Meningeal dissemination in primary CNS lymphoma: Prospective evaluation of 282 patients
    • Fischer L, Martus P, Weller M, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008;71(14):1102-1108.
    • (2008) Neurology , vol.71 , Issue.14 , pp. 1102-1108
    • Fischer, L.1    Martus, P.2    Weller, M.3
  • 46
    • 14844321659 scopus 로고    scopus 로고
    • Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients
    • Küker W, Nägele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72(2):169-177.
    • (2005) J Neurooncol , vol.72 , Issue.2 , pp. 169-177
    • Küker, W.1    Nägele, T.2    Korfel, A.3
  • 47
    • 44849140761 scopus 로고    scopus 로고
    • Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: A pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma
    • Porter AB, Giannini C, Kaufmann T, et al. Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma. Ann Neurol. 2008;63(5):662-667.
    • (2008) Ann Neurol , vol.63 , Issue.5 , pp. 662-667
    • Porter, A.B.1    Giannini, C.2    Kaufmann, T.3
  • 48
    • 0031048110 scopus 로고    scopus 로고
    • Glucocorticoid-induced long-term remission in primary cerebral lymphoma: Case report and review of the literature
    • Pirotte B, Levivier M, Goldman S, Brucher JM, Brotchi J, Hildebrand J. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol. 1997;32(1):63-69.
    • (1997) J Neurooncol , vol.32 , Issue.1 , pp. 63-69
    • Pirotte, B.1    Levivier, M.2    Goldman, S.3    Brucher, J.M.4    Brotchi, J.5    Hildebrand, J.6
  • 49
    • 79953103395 scopus 로고    scopus 로고
    • Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system
    • Baraniskin A, Kuhnhenn J, Schlegel U, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140-3146.
    • (2011) Blood , vol.117 , Issue.11 , pp. 3140-3146
    • Baraniskin, A.1    Kuhnhenn, J.2    Schlegel, U.3
  • 50
    • 0030063206 scopus 로고    scopus 로고
    • Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion
    • Ferreri AJ, Reni M, Zoldan MC, Terreni MR, Villa E. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer. 1996;77(5):827-833.
    • (1996) Cancer , vol.77 , Issue.5 , pp. 827-833
    • Ferreri, A.J.1    Reni, M.2    Zoldan, M.C.3    Terreni, M.R.4    Villa, E.5
  • 51
    • 44849085812 scopus 로고    scopus 로고
    • The utility of body FDG PET in staging primary central nervous system lymphoma
    • Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro-oncol. 2008;10(2):223-228.
    • (2008) Neuro-oncol , vol.10 , Issue.2 , pp. 223-228
    • Mohile, N.A.1    Deangelis, L.M.2    Abrey, L.E.3
  • 52
    • 24644432553 scopus 로고    scopus 로고
    • Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
    • International Primary CNS Lymphoma Collaborative Group
    • Abrey LE, Batchelor TT, Ferreri AJ, et al International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043.
    • (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 5034-5043
    • Abrey, L.E.1    Batchelor, T.T.2    Ferreri, A.J.3
  • 53
    • 82355164767 scopus 로고    scopus 로고
    • Primary vitreoretinal lymphoma: A report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium
    • Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589-1599.
    • (2011) Oncologist , vol.16 , Issue.11 , pp. 1589-1599
    • Chan, C.C.1    Rubenstein, J.L.2    Coupland, S.E.3
  • 55
    • 0037440231 scopus 로고    scopus 로고
    • Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience
    • Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266-272.
    • (2003) J Clin Oncol , vol.21 , Issue.2 , pp. 266-272
    • Ferreri, A.J.1    Blay, J.Y.2    Reni, M.3
  • 56
    • 34247342137 scopus 로고    scopus 로고
    • Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model
    • Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711-5715.
    • (2006) J Clin Oncol , vol.24 , Issue.36 , pp. 5711-5715
    • Abrey, L.E.1    Ben-Porat, L.2    Panageas, K.S.3
  • 58
    • 0033965213 scopus 로고    scopus 로고
    • Primary intracerebral malignant lymphoma: Report of 248 cases
    • Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92(2):261-266.
    • (2000) J Neurosurg , vol.92 , Issue.2 , pp. 261-266
    • Bataille, B.1    Delwail, V.2    Menet, E.3
  • 59
    • 84869188024 scopus 로고    scopus 로고
    • Surgery for primary CNS lymphoma? Challenging a paradigm
    • German PCNSL Study Group
    • Weller M, Martus P, Roth P, Thiel E, Korfel A; German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-oncol. 2012;14(12):1481-1484.
    • (2012) Neuro-oncol , vol.14 , Issue.12 , pp. 1481-1484
    • Weller, M.1    Martus, P.2    Roth, P.3    Thiel, E.4    Korfel, A.5
  • 60
    • 84870875769 scopus 로고    scopus 로고
    • Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article
    • Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012;117(6):1032-1038.
    • (2012) J Neurosurg , vol.117 , Issue.6 , pp. 1032-1038
    • Bloch, O.1    Han, S.J.2    Cha, S.3
  • 61
    • 0026653255 scopus 로고
    • Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
    • Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17.
    • (1992) Int J Radiat Oncol Biol Phys , vol.23 , Issue.1 , pp. 9-17
    • Nelson, D.F.1    Martz, K.L.2    Bonner, H.3
  • 62
    • 0031887689 scopus 로고    scopus 로고
    • Long-term survival in primary CNS lymphoma
    • Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16(3):859-863.
    • (1998) J Clin Oncol , vol.16 , Issue.3 , pp. 859-863
    • Abrey, L.E.1    DeAngelis, L.M.2    Yahalom, J.3
  • 63
    • 79951963826 scopus 로고    scopus 로고
    • Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis
    • Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29(3):279-286.
    • (2011) J Clin Oncol , vol.29 , Issue.3 , pp. 279-286
    • Sun, A.1    Bae, K.2    Gore, E.M.3
  • 64
    • 0018842103 scopus 로고
    • Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate
    • Ervin T, Canellos GP. Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer. 1980;45(7):1556-1557.
    • (1980) Cancer , vol.45 , Issue.7 , pp. 1556-1557
    • Ervin, T.1    Canellos, G.P.2
  • 65
    • 0017724793 scopus 로고
    • High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement
    • Skarin AT, Zuckerman KS, Pitman SW, et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977;50(6):1039-1047.
    • (1977) Blood , vol.50 , Issue.6 , pp. 1039-1047
    • Skarin, A.T.1    Zuckerman, K.S.2    Pitman, S.W.3
  • 66
    • 0036125535 scopus 로고    scopus 로고
    • Central nervous system relapse of systemic non-Hodgkin's lymphoma: Results of treatment based on high-dose methotrexate combination chemotherapy
    • Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43(3):587-593.
    • (2002) Leuk Lymphoma , vol.43 , Issue.3 , pp. 587-593
    • Bokstein, F.1    Lossos, A.2    Lossos, I.S.3    Siegal, T.4
  • 67
    • 0031887536 scopus 로고    scopus 로고
    • High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
    • Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16(3):864-871.
    • (1998) J Clin Oncol , vol.16 , Issue.3 , pp. 864-871
    • Blay, J.Y.1    Conroy, T.2    Chevreau, C.3
  • 68
    • 0036063821 scopus 로고    scopus 로고
    • Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    • Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol. 2002;58(2):175-178.
    • (2002) J Neurooncol , vol.58 , Issue.2 , pp. 175-178
    • Khan, R.B.1    Shi, W.2    Thaler, H.T.3    DeAngelis, L.M.4    Abrey, L.E.5
  • 69
    • 0642316783 scopus 로고    scopus 로고
    • Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-totreat analysis
    • Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-totreat analysis. J Clin Oncol. 2003;21(22):4151-4156.
    • (2003) J Clin Oncol , vol.21 , Issue.22 , pp. 4151-4156
    • Abrey, L.E.1    Moskowitz, C.H.2    Mason, W.P.3
  • 70
    • 0030011021 scopus 로고    scopus 로고
    • Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results
    • Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology. 1996;46(6):1757-1759.
    • (1996) Neurology , vol.46 , Issue.6 , pp. 1757-1759
    • Cher, L.1    Glass, J.2    Harsh, G.R.3    Hochberg, F.H.4
  • 71
    • 4444269516 scopus 로고    scopus 로고
    • Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
    • Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643-5646.
    • (2004) Clin Cancer Res , vol.10 , Issue.17 , pp. 5643-5646
    • Plotkin, S.R.1    Betensky, R.A.2    Hochberg, F.H.3
  • 72
    • 0037445256 scopus 로고    scopus 로고
    • Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07
    • Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044-1049.
    • (2003) J Clin Oncol , vol.21 , Issue.6 , pp. 1044-1049
    • Batchelor, T.1    Carson, K.2    O'Neill, A.3
  • 73
    • 84875359514 scopus 로고    scopus 로고
    • Glucarpidase to combat toxic levels of methotrexate in patients
    • Green JM. Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403-413.
    • (2012) Ther Clin Risk Manag , vol.8 , pp. 403-413
    • Green, J.M.1
  • 74
    • 0037115536 scopus 로고    scopus 로고
    • Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10
    • Radiation Therapy Oncology Group Study 93-10
    • DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20(24):4643-4648.
    • (2002) J Clin Oncol , vol.20 , Issue.24 , pp. 4643-4648
    • DeAngelis, L.M.1    Seiferheld, W.2    Schold, S.C.3    Fisher, B.4    Schultz, C.J.5
  • 75
    • 0026531942 scopus 로고
    • Combined modality therapy for primary CNS lymphoma
    • DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635-643.
    • (1992) J Clin Oncol , vol.10 , Issue.4 , pp. 635-643
    • DeAngelis, L.M.1    Yahalom, J.2    Thaler, H.T.3    Kher, U.4
  • 76
    • 0027939601 scopus 로고
    • Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Longterm outcome
    • Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: longterm outcome. J Neurosurg. 1994;81(2):188-195.
    • (1994) J Neurosurg , vol.81 , Issue.2 , pp. 188-195
    • Glass, J.1    Gruber, M.L.2    Cher, L.3    Hochberg, F.H.4
  • 77
    • 70350567171 scopus 로고    scopus 로고
    • High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial
    • International Extranodal Lymphoma Study Group (IELSG)
    • Ferreri AJ, Reni M, Foppoli M, et al International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512-1520.
    • (2009) Lancet , vol.374 , Issue.9700 , pp. 1512-1520
    • Ferreri, A.J.1    Reni, M.2    Foppoli, M.3
  • 78
    • 20444424511 scopus 로고    scopus 로고
    • NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report
    • Neuro-Oncology Working Group of the German Society
    • Herrlinger U, Küker W, Uhl M, et al Neuro-Oncology Working Group of the German Society. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57(6):843-847.
    • (2005) Ann Neurol , vol.57 , Issue.6 , pp. 843-847
    • Herrlinger, U.1    Küker, W.2    Uhl, M.3
  • 79
    • 78049528113 scopus 로고    scopus 로고
    • High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial
    • Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-1047.
    • (2010) Lancet Oncol , vol.11 , Issue.11 , pp. 1036-1047
    • Thiel, E.1    Korfel, A.2    Martus, P.3
  • 80
    • 0035253506 scopus 로고    scopus 로고
    • Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma
    • Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19(3):742-749.
    • (2001) J Clin Oncol , vol.19 , Issue.3 , pp. 742-749
    • Soussain, C.1    Suzan, F.2    Hoang-Xuan, K.3
  • 81
    • 0033660953 scopus 로고    scopus 로고
    • High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma
    • Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6(3A):352-358.
    • (2000) Biol Blood Marrow Transplant , vol.6 , Issue.3 , pp. 352-358
    • Alvarnas, J.C.1    Negrin, R.S.2    Horning, S.J.3
  • 82
    • 0026000386 scopus 로고
    • Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma
    • Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer. 1991;27(11):1356-1361.
    • (1991) Eur J Cancer , vol.27 , Issue.11 , pp. 1356-1361
    • Ott, R.J.1    Brada, M.2    Flower, M.A.3    Babich, J.W.4    Cherry, S.R.5    Deehan, B.J.6
  • 83
    • 0034607260 scopus 로고    scopus 로고
    • Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma
    • Reni M, Ferreri AJ, Landoni C, Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst. 2000;92(7):575-576.
    • (2000) J Natl Cancer Inst , vol.92 , Issue.7 , pp. 575-576
    • Reni, M.1    Ferreri, A.J.2    Landoni, C.3    Villa, E.4
  • 84
    • 33947434049 scopus 로고    scopus 로고
    • Temozolomide as salvage treatment in primary brain lymphomas
    • Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864-867.
    • (2007) Br J Cancer , vol.96 , Issue.6 , pp. 864-867
    • Reni, M.1    Zaja, F.2    Mason, W.3
  • 85
    • 3042621791 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas
    • Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101(1):139-145.
    • (2004) Cancer , vol.101 , Issue.1 , pp. 139-145
    • Wong, E.T.1    Tishler, R.2    Barron, L.3    Wu, J.K.4
  • 86
    • 0033898465 scopus 로고    scopus 로고
    • Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide
    • Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000;36(14):1788-1795.
    • (2000) Eur J Cancer , vol.36 , Issue.14 , pp. 1788-1795
    • Osoba, D.1    Brada, M.2    Yung, W.K.3    Prados, M.D.4
  • 87
    • 0034034511 scopus 로고    scopus 로고
    • Healthrelated quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme
    • Osoba D, Brada M, Yung WK, Prados M. Healthrelated quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18(7):1481-1491.
    • (2000) J Clin Oncol , vol.18 , Issue.7 , pp. 1481-1491
    • Osoba, D.1    Brada, M.2    Yung, W.K.3    Prados, M.4
  • 88
    • 74949115388 scopus 로고    scopus 로고
    • Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909
    • Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.
    • (2009) J Clin Oncol , vol.27 , Issue.36 , pp. 6101-6108
    • Damon, L.E.1    Johnson, J.L.2    Niedzwiecki, D.3
  • 89
    • 57049135254 scopus 로고    scopus 로고
    • Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma
    • Damon L, Damon LE, Gaensler K, et al. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008;42(10):649-657.
    • (2008) Bone Marrow Transplant , vol.42 , Issue.10 , pp. 649-657
    • Damon, L.1    Damon, L.E.2    Gaensler, K.3
  • 90
    • 70349583839 scopus 로고    scopus 로고
    • Auto-SCT for AML in second remission: CALGB study 9620
    • Cancer and Leukemia Group B
    • Linker CA, Owzar K, Powell B, et al; Cancer and Leukemia Group B. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009;44(6):353-359.
    • (2009) Bone Marrow Transplant , vol.44 , Issue.6 , pp. 353-359
    • Linker, C.A.1    Owzar, K.2    Powell, B.3
  • 91
    • 0027182362 scopus 로고
    • EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
    • Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11(8):1573-1582.
    • (1993) J Clin Oncol , vol.11 , Issue.8 , pp. 1573-1582
    • Wilson, W.H.1    Bryant, G.2    Bates, S.3
  • 92
    • 45749152667 scopus 로고    scopus 로고
    • Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    • Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717-2724.
    • (2008) J Clin Oncol , vol.26 , Issue.16 , pp. 2717-2724
    • Wilson, W.H.1    Dunleavy, K.2    Pittaluga, S.3
  • 93
    • 0030040519 scopus 로고    scopus 로고
    • Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia
    • Relling MV, Mahmoud HH, Pui CH, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(2):399-404.
    • (1996) J Clin Oncol , vol.14 , Issue.2 , pp. 399-404
    • Relling, M.V.1    Mahmoud, H.H.2    Pui, C.H.3
  • 94
    • 33846531961 scopus 로고    scopus 로고
    • Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    • German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    • Boehme V, Zeynalova S, Kloess M, et al German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157.
    • (2007) Ann Oncol , vol.18 , Issue.1 , pp. 149-157
    • Boehme, V.1    Zeynalova, S.2    Kloess, M.3
  • 96
    • 3242714878 scopus 로고    scopus 로고
    • Ocular presentation of primary central nervous system lymphoma: Diagnosis and treatment
    • Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126(2):202-208.
    • (2004) Br J Haematol , vol.126 , Issue.2 , pp. 202-208
    • Hormigo, A.1    Abrey, L.2    Heinemann, M.H.3    DeAngelis, L.M.4
  • 97
    • 27544491698 scopus 로고    scopus 로고
    • Diagnostic delay in primary central nervous system lymphoma
    • Haldorsen IS, Espeland A, Larsen JL, Mella O. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005;44(7):728-734.
    • (2005) Acta Oncol , vol.44 , Issue.7 , pp. 728-734
    • Haldorsen, I.S.1    Espeland, A.2    Larsen, J.L.3    Mella, O.4
  • 98
    • 58149354864 scopus 로고    scopus 로고
    • Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20-year follow-up analysis of SWOG 8516 - The Southwest Oncology Group
    • Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 - the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-119.
    • (2009) J Clin Oncol , vol.27 , Issue.1 , pp. 114-119
    • Bernstein, S.H.1    Unger, J.M.2    Leblanc, M.3    Friedberg, J.4    Miller, T.P.5    Fisher, R.I.6
  • 99
    • 0031923886 scopus 로고    scopus 로고
    • High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary?
    • Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16(4):1561-1567.
    • (1998) J Clin Oncol , vol.16 , Issue.4 , pp. 1561-1567
    • Glantz, M.J.1    Cole, B.F.2    Recht, L.3
  • 100
    • 77957331593 scopus 로고    scopus 로고
    • Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma
    • Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283-4290.
    • (2010) Cancer , vol.116 , Issue.18 , pp. 4283-4290
    • Abramson, J.S.1    Hellmann, M.2    Barnes, J.A.3
  • 101
    • 45149086329 scopus 로고    scopus 로고
    • Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire
    • Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512-2518.
    • (2008) J Clin Oncol , vol.26 , Issue.15 , pp. 2512-2518
    • Soussain, C.1    Hoang-Xuan, K.2    Taillandier, L.3
  • 102
    • 84855417603 scopus 로고    scopus 로고
    • Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma
    • Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18(1):76-83.
    • (2012) Biol Blood Marrow Transplant , vol.18 , Issue.1 , pp. 76-83
    • Cote, G.M.1    Hochberg, E.P.2    Muzikansky, A.3
  • 103
    • 84865522655 scopus 로고    scopus 로고
    • Highdose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma
    • Falzetti F, Di Ianni M, Ballanti S, et al. Highdose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med. 2012;12(3):165-171.
    • (2012) Clin Exp Med , vol.12 , Issue.3 , pp. 165-171
    • Falzetti, F.1    Di Ianni, M.2    Ballanti, S.3
  • 104
    • 9144223630 scopus 로고    scopus 로고
    • Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab
    • Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-133.
    • (2004) Ann Oncol , vol.15 , Issue.1 , pp. 129-133
    • Feugier, P.1    Virion, J.M.2    Tilly, H.3
  • 105
    • 79960283082 scopus 로고    scopus 로고
    • Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre- and postrituximab
    • Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and postrituximab. Ann Hematol. 2011;90(7):809-818.
    • (2011) Ann Hematol , vol.90 , Issue.7 , pp. 809-818
    • Tai, W.M.1    Chung, J.2    Tang, P.L.3
  • 106
    • 77953867584 scopus 로고    scopus 로고
    • Central nervous system involvement in diffuse large B-cell lymphoma
    • Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol. 2010;85(1):6-10.
    • (2010) Eur J Haematol , vol.85 , Issue.1 , pp. 6-10
    • Yamamoto, W.1    Tomita, N.2    Watanabe, R.3
  • 107
    • 0037438494 scopus 로고    scopus 로고
    • Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment
    • Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466-468.
    • (2003) Blood , vol.101 , Issue.2 , pp. 466-468
    • Rubenstein, J.L.1    Combs, D.2    Rosenberg, J.3
  • 108
    • 34248173334 scopus 로고    scopus 로고
    • Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma
    • Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007;25(11):1350-1356.
    • (2007) J Clin Oncol , vol.25 , Issue.11 , pp. 1350-1356
    • Rubenstein, J.L.1    Fridlyand, J.2    Abrey, L.3
  • 109
    • 84873544339 scopus 로고    scopus 로고
    • Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
    • Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121(5):745-751.
    • (2013) Blood , vol.121 , Issue.5 , pp. 745-751
    • Rubenstein, J.L.1    Li, J.2    Chen, L.3
  • 110
    • 36048998775 scopus 로고    scopus 로고
    • Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma
    • Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730-4735.
    • (2007) J Clin Oncol , vol.25 , Issue.30 , pp. 4730-4735
    • Shah, G.D.1    Yahalom, J.2    Correa, D.D.3
  • 111
    • 31644446964 scopus 로고    scopus 로고
    • The pharmacokinetics of rituximab following an intravitreal injection
    • Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82(5):760-766.
    • (2006) Exp Eye Res , vol.82 , Issue.5 , pp. 760-766
    • Kim, H.1    Csaky, K.G.2    Chan, C.C.3
  • 112
    • 34548529143 scopus 로고    scopus 로고
    • Treatment outcomes for primary intraocular lymphoma: Implications for external beam radiotherapy
    • Berenbom A, Davila RM, Lin HS, Harbour JW. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond). 2007;21(9):1198-1201.
    • (2007) Eye (Lond) , vol.21 , Issue.9 , pp. 1198-1201
    • Berenbom, A.1    Davila, R.M.2    Lin, H.S.3    Harbour, J.W.4
  • 113
  • 114
    • 63249103710 scopus 로고    scopus 로고
    • Rituximab for intraocular lymphoma
    • Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina. 2009;29(2):129-132.
    • (2009) Retina , vol.29 , Issue.2 , pp. 129-132
    • Itty, S.1    Pulido, J.S.2
  • 116
    • 67349239314 scopus 로고    scopus 로고
    • Ifosfamide or trofosfamide in patients with intraocular lymphoma
    • Jahnke K, Thiel E, Bechrakis NE, et al. Ifosfamide or trofosfamide in patients with intraocular lymphoma. J Neurooncol. 2009;93(2):213-217.
    • (2009) J Neurooncol , vol.93 , Issue.2 , pp. 213-217
    • Jahnke, K.1    Thiel, E.2    Bechrakis, N.E.3
  • 117
    • 77956862249 scopus 로고    scopus 로고
    • Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: A single-institution experience
    • Stefanovic A, Davis J, Murray T, Markoe A, Lossos IS. Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single-institution experience. Br J Haematol. 2010;151(1):103-106.
    • (2010) Br J Haematol , vol.151 , Issue.1 , pp. 103-106
    • Stefanovic, A.1    Davis, J.2    Murray, T.3    Markoe, A.4    Lossos, I.S.5
  • 118
    • 0030781411 scopus 로고    scopus 로고
    • Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS
    • Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS. 1997;11(14):1725-1730.
    • (1997) AIDS , vol.11 , Issue.14 , pp. 1725-1730
    • Jacomet, C.1    Girard, P.M.2    Lebrette, M.G.3    Farese, V.L.4    Monfort, L.5    Rozenbaum, W.6
  • 119
    • 84888021418 scopus 로고    scopus 로고
    • Unpublished Observations. Manuscript in Preparation
    • Gupta N, Hwang J, Rubenstein JL. Unpublished Observations. Manuscript in Preparation.
    • Gupta, N.1    Hwang, J.2    Rubenstein, J.L.3
  • 120
    • 33644891006 scopus 로고    scopus 로고
    • Treatment of PTLD with rituximab or chemotherapy
    • Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6(3):569-576.
    • (2006) Am J Transplant , vol.6 , Issue.3 , pp. 569-576
    • Elstrom, R.L.1    Andreadis, C.2    Aqui, N.A.3
  • 121
    • 40449100681 scopus 로고    scopus 로고
    • Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system
    • van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer. 2008;50(4):886-888.
    • (2008) Pediatr Blood Cancer , vol.50 , Issue.4 , pp. 886-888
    • Van De Glind, G.1    De Graaf, S.2    Klein, C.3    Cornelissen, M.4    Maecker, B.5    Loeffen, J.6
  • 122
    • 84878298292 scopus 로고    scopus 로고
    • Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma
    • He M, Zuo C, Wang J, et al. Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. Neuro-oncol. 2013;15(6):727-734.
    • (2013) Neuro-oncol , vol.15 , Issue.6 , pp. 727-734
    • He, M.1    Zuo, C.2    Wang, J.3
  • 123
    • 79953764895 scopus 로고    scopus 로고
    • Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma
    • Sung KH, Lee EH, Kim YZ. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma. J Korean Med Sci. 2011;26(4):551-560.
    • (2011) J Korean Med Sci , vol.26 , Issue.4 , pp. 551-560
    • Sung, K.H.1    Lee, E.H.2    Kim, Y.Z.3
  • 124
    • 75749155906 scopus 로고    scopus 로고
    • Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma
    • Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31(1):60-66.
    • (2010) AJNR Am J Neuroradiol , vol.31 , Issue.1 , pp. 60-66
    • Barajas Jr., R.F.1    Rubenstein, J.L.2    Chang, J.S.3    Hwang, J.4    Cha, S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.